Maze Therapeutics (NASDAQ:MAZE) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Maze Therapeutics (NASDAQ:MAZE) from a hold rating to a sell rating in a research note published on Saturday morning.

Several other equities research analysts have also recently issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 target price on the stock. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Wedbush raised their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $44.50.

Maze Therapeutics Stock Performance

MAZE stock opened at $45.03 on Friday. The stock’s 50 day moving average price is $41.74 and its 200 day moving average price is $30.10. The firm has a market cap of $2.17 billion and a P/E ratio of -2.15. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $49.25.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Activity at Maze Therapeutics

In other news, CMO Harold Bernstein sold 45,000 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 200,000 shares of company stock worth $8,254,792.

Institutional Investors Weigh In On Maze Therapeutics

Several large investors have recently made changes to their positions in MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Maze Therapeutics during the 1st quarter valued at $57,000. Goldman Sachs Group Inc. acquired a new position in shares of Maze Therapeutics during the first quarter worth about $145,000. Rhumbline Advisers purchased a new stake in shares of Maze Therapeutics in the first quarter worth about $80,000. CWM LLC acquired a new stake in shares of Maze Therapeutics in the second quarter valued at about $28,000. Finally, Geode Capital Management LLC raised its holdings in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after buying an additional 18,773 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.